articleTop 10% cited

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

Gynecologic Oncology · 1990 · Vol. 36(2) · pp. 207–211

Martin Gore✉I Fryatt(Royal Marsden Hospital)E. Wiltshaw(Royal Marsden NHS Foundation Trust)Timothy Dawson(Royal Marsden Hospital)

View via DOI Publisher page

Ovarian cancer diagnosis and treatment Reproductive Biology and Fertility Endometriosis Research and TreatmentMedicineCarboplatinCisplatinInternal medicineOvaryOvarian cancerChemotherapyGastroenterologySignificant differenceOncology

MeSH terms

Antineoplastic AgentsCarcinomaCisplatinFemaleHumansNeoplasm Recurrence, LocalOrganoplatinum CompoundsOvarian NeoplasmsPrognosisSurvivalTime FactorsCarboplatin

Citations

391

FWCI

10.23

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?

Gynecologic Oncology · 2014 · 437 citations

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

Gynecologic Oncology · 2004 · 431 citations

New Cisplatin Analogues in Development

Drugs · 1993 · 402 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.